


BETA LACTAM ANTIBIOTICS

- ▶ **PENICILLINS**
- ▶ **CEPHALOSPORINS**
- ▶ **MONOBACTAMS**
- ▶ **CARBAPENEMS**

Alexander Flemming Inventor of penicillin



- ▶ ORIGINALLY OBTAINED FROM FUNGUS *PENICILLIUM NOTATUM*.
- ▶ DISCOVERED IN 1928.

- ▶ AL. FLEMMING WAS WORKING IN HIS LAB TRYING TO KILL A DEADLY BACTERIA WHEN HE NOTICED A BLUE MOULD GROWING ON THE DISH (NOTATUM), AROUND THAT BACTERIA WERE GETTING KILLED.
- ▶ PENICILLIN FOUND IN THIS MOULD
- ▶ NOW FROM *P.CHRYSOGENUM* BECAUSE AMOUNT GOT FROM NOTATUM NOT SUFFICIENT.


Penicillin



The mould *Penicillium notatum*

Structure

PENICILLIN



A THIAZOLIDINE RING (A) ATTACHED TO β -LACTAM RING (B) THAT CARRIES A SECONDARY AMINO GROUP

STRUCTURE

- ▶ β LACTAM RING CARRIES A SECONDARY AMINO GROUP TO WHICH SIDE CHAINS ATTACHED THROUGH AN AMIDE LINKAGE.
- ▶ PEN.G (PROTOTYPE)
 - BENZYL SIDE CHAIN.
- ▶ SIDE CHAINS SPLIT OFF BY AN AMIDASE TO PRODUCE –
- ▶ 6-AMINOPENCILLANIC ACID.

PENCILLIN -G (BENZYL PENICILLIN)

- ▶ A narrow spectrum antibiotic
- ▶ Mainly against gram positive bacteria
- ▶ Streptococci
- ▶ Pneumococci
- ▶ B.Anthraxis
- ▶ Corynebacterium diphtheriae
- ▶ Clostridia
- ▶ Listeria
- ▶ Treponema pallidum
- ▶ Actinomyces israelii
- ▶ Gram negative cocci – N.gonorrhoeae and meningitidis

P/K (PEN. G)

- ▶ Pen.G is acid labile.
Give 30 min before or 2 hrs after meals.
- ▶ Very rapid renal excretion
- ▶ 10% by glomerular filtration
- ▶ Rest by tubular secretion (ts)
- ▶ Ts can be blocked by probenecid
- ▶ To get higher and longer lasting plasma conc.

P/K (contd.)

- ▶ Insoluble salts of pen.G.
- ▶ Repository prep : release pen.G slowly.
- ▶ Given deep i/m.

- ▶ **Procaine pen.** 0.5 – 1 mu, 12–24 hrly as aq. suspension.
- ▶ Plasma conc. Sustained for 1–2 days.

P/K

- ▶ **BENZATHINE PEN. –**
- ▶ Extremely slow release of pen.
- ▶ 0.6–2.4 mu every 2– 4 wks.
- ▶ Effective for prophylactic purposes for upto 4 wks.

USES OF PEN.G

1. Streptococcal infections: Pharyngitis, otitis media, scarlet fever, rheumatic fever.
2. Pneumococcal infections
3. Meningococcal infections
4. Anthrax, gas gangrene, diphtheria, syphilis, tetanus.
5. Gonorrhoea

USES

6. Prophylactic use–

A) Rheumatic fever: Benzathine pen. : 1.2 MU every 4 wks till 18 years of age.

B) Gonorrhoea or syphilis : Procaine or Benzathine pen. 2.4 MU single dose within 12 hrs of contact .

USES contd.

7. Bacterial endocarditis –
extractions, endoscopies, catheterization,
surgical procedures.
8. Agranulocytosis – alone or in
combination.
9. Surgical infections – Procaine pen. 1 MU
with an aminoglycoside injected i.m 1 hr
before and 8–12 hrs after surgery can
reduce wound infections.


MECHANISM OF ACTION

- ▶ Interferes with last step of synthesis of cell wall that is – transpeptidation or cross linkage
- ▶ Cell wall deficient forms of bact. Are formed which swell and burst – bacterial lysis.
- ▶ Bactericidal action
- ▶ Inhibits ENZYME, PENICILLIN BINDING PROTEINS, pbps, INVOLVED IN SYN.Of cell wall.

MECHANISM OF ACTION

- ▶ PBPS catalyse formation of cross linkages between peptidoglycan chains.
- ▶ Penicillins inhibit transpeptidase-catalysed reactions ,thus hindering the formation of cross links essential for cell wall integrity and close knit structure of cell wall.
- ▶ Effective only against multiplying org. As resting org. are not making new cell wall

MOA



MOA

- ▶ Polysaccharides in the cell wall contain alternating amino sugars ---
- ▶ N-acetylglucosamine & N-acetylmuramic acid.
- ▶ A five amino acid peptide is linked to N-acetylmuramic acid sugar.
- ▶ This peptide terminates in D-alanyl-D-alanine.

- ▶ PBP removes the terminal alanine in the process of forming a cross link with a nearby peptide .
- ▶ Cross– links give the cell wall its structural rigidity.
- ▶ Beta lactam antibiotics, structural analogs of the D–ala–D–ala substrate, bind to active site of PBP.
- ▶ This inhibits the trans–peptidation reaction
- ▶ Preventing the peptidoglycan synthesis and cell dies.




Figure 43-1. Beta-lactams and bacterial cell wall synthesis. The outer membrane shown in this simplified diagram is present only in gram-negative organisms. It is penetrated by proteins (porins) that are permeable to hydrophilic substances such as beta-lactam antibiotics. The peptidoglycan chains (mureins) are cross-linked by transpeptidases located in the cytoplasmic membrane, closely associated with penicillin-binding proteins (PBPs). Beta-lactam antibiotics bind to PBPs and inhibit transpeptidation, the final step in cell wall synthesis. They also activate autolytic enzymes that cause lesions in the cell wall. Beta-lactamases, which inactivate beta-lactam antibiotics, may be present in the periplasmic space or on the outer surface of the cytoplasmic membrane. (Reproduced, with permission, from Katzung BG, editor: *Basic & Clinical Pharmacology*, 10th ed. McGraw-Hill, 2007.)




Figure 49.2 Schematic diagram of a single layer of peptidoglycan from a bacterial cell (e.g. *Staphylococcus aureus*), showing the site of action of the β -lactam antibiotics. In *S. aureus*, the peptide crosslinks consist of five glycine residues. Gram-positive bacteria have several layers of peptidoglycan. (NAG, N-acetylglucosamine; NAMA, N-acetylmuramic acid; more detail in Fig. 49.3.)

BACTERIAL RESISTANCE

- ▶ **TARGET INSENSITIVE**
PBP_s WITH LOW AFFINITY FOR BINDING BETA LACTAMS,
- ▶ **LOCATED DEEPER UNDER LIPOPROTEIN BARRIER.**

- ▶ **IMPAIRED PENETRATION OF DRUG TO TARGET PBP.**
- ▶ **OCCURS IN GRAM NEGATIVE BACT DUE TO IMPERMEABLE OUTER CELLWALL MEMBRANE**

BACTERIAL RESISTANCE

- ▶ PENICILLINASE PRODUCTION
- ▶ INACTIVATION OF ANTIBIOTIC BY β LACTAMASES
- ▶ STAPH, GONOCOCCI, B.SUBTILIS, E.COLI, H.INFLUENZAE PRODUCE PENCILLINASE.

- ▶ EFFLUX- GRAM NEGATIVE ORGANISMS MAY PRODUCE AN EFFLUX PUMP WHICH TRANSPORT β LACTAM ANTIBIOTICS FROM THE PERIPLASM BACK ACROSS THE OUTER MEMBRANE.

Adverse drug reactions

- ▶ **Hypersensitivity**
- ▶ Most common drug implicated in drug allergy
- ▶ Rash, itching, urticaria , fever, wheezing, angioneurotic edema , serum sickness exfoliative dermatitis and anaphylaxis, Rare but fatal.
- ▶ More common with parenteral administration.
- ▶ Highest with procaine penicillin .

- ▶ Partial cross sensitivity b/w different types
- ▶ A scratch test or intradermal test
- ▶ TEST WITH BENZYL- PENICILLOYL POLYLYSINE , serves as a hapten to cause an immune reaction.
- ▶ Topical use highly sensitising,
- ▶ Contact dermatitis and other reactions, so banned.

- ▶ Pain at inj site
- ▶ Thrombophlebitis of injected vein
- ▶ Nausea on oral use
- ▶ Diarrhoea – with extended spectrum penicillin, caused by a disruption of the normal balance of intestinal organisms. Ampicillin has been associated with pseudo-membranous colitis.
- ▶ **Toxicity to brain :**
- ▶ mental confusion, Muscle twitchings
- ▶ Convulsions & coma
- ▶ Epileptics are at risk particularly.

- ▶ **Nephritis** – all can cause but seen particularly with methicillin, so not used.
- ▶ **Hematologic toxicities** – decreased coagulation with antipseudomonal ,to some extent with Pen.G . caution in pts who are predisposed to hemorrhage , or receiving anticoagulants.

▶ **JARISCH-HERXHEIMER REACTION-**

PENICILLIN INJECTED IN A SYPHILITIC PATIENT – SHIVERING , FEVER , MYALGIA , EXACERBATION OF LESIONS & VASCULAR COLLAPSE.

DUE TO SUDDEN RELEASE OF SPIROCHAETAL LYTIC PRODUCTS AND LASTS FOR 12- 24 HRS ASPIRIN AND SEDATION HELP.

SEMISYNTHETIC PENICILLINS

- ▶ PRODUCED BY CHEMICALLY COMBINING SPECIFIC SIDE CHAINS
- ▶ AIM IS TO OVERCOME SHORTCOMINGS OF PnG –
- ▶ POOR ORAL EFFICACY
- ▶ SUSCEPTIBILITY TO PENCILLINASE
- ▶ NARROW SPECTRUM OF ACTIVITY
- ▶ HYPERSENSITIVITY

CLASSIFICATION

- ▶ **ACID RESISTANT ALTERNATIVE TO PnG**
- ▶ Penicillin V
- ▶ **PENICILLINASE RESISTANCE PENICILLINS**
- ▶ Methicilin, oxacillin, cloxacillin, dicloxacillin
- ▶ **EXTENDED SPECTRUM PENICILLINS**
- ▶ a) **AMINOPENICILLINS** : Ampicillin, Bacampicillin, Amoxicillin
- ▶ b) **CARBOXPENICILLINS**: Carbenicillin, carbenicillin indanyl & phenyl, Ticarcillin
- ▶ c) **UREIDOPENICILLINS** : Piperacillin, Mezlocillin

Penicillin V (Phenoxy Methyl Pen.V)

- ▶ **ACID STABLE**
- ▶ 1 /5th AS ACTIVE AG.NEISSERIA, OTHER GRAM NEGATIVE BACTERIA AND ANEROBES .
- ▶ **USED ONLY FOR–**
- ▶ ***STREP.PHARYNGITIS*, SINUSITIS & OTITIS MEDIA**
- ▶ **PROPHYLAXIS OF RHEUMATIC FEVER**
- ▶ **PNEMOCOCCAL INFECTIONS**

PENICILLINASE RESISTANT PENICILLINS

- ▶ **ANTI – STAPHYLOCOCCAL PEN.**
Have side chains that protect beta lactam ring from attack by staphylococcal penicillinase.
- ▶ **Indication – Penicillinase producing staph**
- ▶ **METHICILLIN –**
- ▶ **HIGHLY PENICILLINASE RESISTANT**
- ▶ **NOT ACID RESISTANT– MUST BE INJECTED**
- ▶ **MRSA (Methicillin resistant staph aureus)**

MRSA

- ▶ INSENSITIVE TO ALL PENCILLINASE RESISTANT PEN.
- ▶ HAVE ALTERED PBP_s WHICH DO NOT BIND PENICILLINS
- ▶ DRUG OF CHOICE–
 - ▶ VANCOMYCIN / LINEZOLID
 - ▶ CIPROFLOXACIN

S/Es(methicillin)

- ▶ HAEMATURIA
- ▶ ALBUMINURIA
- ▶ REVERSIBLE INTERSTITIAL NEPHRITIS
- ▶ LARGELY REPLACED BY CLOXACILLIN

ISOXAZOLYL PENICILLINS

- ▶ OXA ,CLOXACILLIN , DICLOXACILLIN
- ▶ ALL RELATIVELY STABLE IN ACIDIC MEDIUM
- ▶ ADEQUATELY ABSORBED AFTER ORAL ADMINISTRATION
- ▶ DICLOXACILLIN MOST ACTIVE
- ▶ ALL LESS ACTIVE AG. ORGANISMS SENSITIVE TO PENICILLIN G

CLOXACILLIN

▶ ISOXAZOLYL SIDE CHAIN

- ▶ Highly penicillinase resistant
- ▶ More active than methicillin against penicillinase resistant staph
- ▶ Relatively acid resistant.
- ▶ However food interferes with absorption so give one hour before or after meals.
- ▶ 0.25– 0.5 g orally every 6 hourly
- ▶ For serious infections 0.25 –1 g injected i.m. or i.v.

PENICILLINASE RESISTANT PEN.contd

- ▶ RAPIDLY ABSORBED FROM GIT
- ▶ RAPIDLY EXCRETED BY KIDNEY
- ▶ HALF LIFE – 30–60 MIN
- ▶ DAILY DOSE OF OXACILLIN– 2–4 g in 4 DIVIDED DOSES
- ▶ DICLOXA – 250 mg EVERY 6 HOURS

- ▶ USED TO TREAT INFECTIONS SUCH AS OSTEOMYELITIS, SEPTICAEMIA , ENDOCARDITIS AND CELLULITIS CAUSED BY SUSCEPTIBLE STRAINS OF **STAPH.**
- ▶ CLOXACILLIN CAN ALSO BE USED TO TREAT MILD STAPHYLOCOCCAL SKIN INFECTIONS SUCH AS IMPETIGO.

AMINOPENICILLINS

- ▶ AMINO SUBSTITUTION IN SIDE CHAIN
- ▶ AMPICILLIN
- ▶ SAME ORGANISMS AG. WHICH PEN.G IS EFFECTIVE
- ▶ GRAM -VE : E.COLI , SALMONELLA,
▶ PROTEUS, SHIGELLA
- ▶ MORE ACTIVE THAN PEN.G AGAINST :
- ▶ STREPT.VIRIDANS & ENTEROCOCCI
- ▶ P/K – NOT DEGRADED BY GASTRIC ACID
- ▶ ADEQUATE ORAL ABSORPTION BUT INCOMPLETE
- ▶ FOOD INTERFERS WITH ABSORPTION
- ▶ PLASMA HALF LIFE – ONE HOUR

AMPICILLIN

- USES – UTI – RESISTANCE,**
FLUOROQUINOLONES/COTRIMOXAZOLE
- ▶ **RTI – SINUSITIS , OTITIS MEDIA, BRONCHITIS**
 - ▶ **DOSE– 0.5–2 g ORAL /I.M. /I.V. 6 HOURLY**
 - ▶ **MENINGITIS – ALONG WITH THIRD GEN.CEPH.**
 - ▶ **GONORRHEA – NPPG**
 - ▶ **TYPHOID FEVER – RESISTANCE**
 - ▶ **BACILLARY DYSENTRY– SHIGELLA (QUINOLONES PREFERRED)**
 - ▶ **CHOLECYSTITIS– HIGH CONC. IN BILE**

AMPICILLIN

- ▶ **S/Es** – diarrhoea, rashes resembling measles or rubella

- ▶ **BACAMPICILLIN**
- ▶ PRODRUG, largely hydrolysed during absorption . Nearly completely absorbed from git.
- ▶ Tissue penetration better.
- ▶ Diarrhoea less (does not disturb intestinal ecology much)

AMOXICILLIN

- ▶ ORAL ABSORPTION IS BETTER. FOOD DOES NOT INTERFERE. HIGHER BLOOD LEVELS FOR LONGER TIME.
- ▶ DIFFERENCES FROM AMPICILLIN–
- ▶ DIARRHEA IS LESS.
- ▶ LESS ACTIVE AG. SHIGELLA AND H.INFLUENZAE.
- ▶ PREFERRED FOR – TYPHOID, UTI , GONORRHEA, BRONCHITIS , SABA.
- ▶ EMPLOYED PROPHYLACTICALLY BY DENTISTS FOR PATIENTS WITH HEART VALVE DS, WHO HAVE TO UNDERGO ORAL SURGERY.
- ▶ DOSE– 250 mg – 1g tds oral

CARBOXY PENICILLINS

CARBENICILLIN

- ▶ ACTIVITY Ag. – PSEUDOMONAS AERUGINOSA
- ▶ – INDOLE POSITIVE PROTEUS
- ▶ USED IN SERIOUS INFECTIONS CAUSED BY THE TWO e.g. Burns, UTI, Septicemia.
- ▶ NEITHER PENICILLINASE RESISTANT NOR ACID RESISTANT.
- ▶ Inactive orally, excreted rapidly in urine .
- ▶ Used as sodium salt
- ▶ Not preferred. Piperacillin preferred.
- ▶ As sodium salt, can cause **fluid retention**, CHF in patients with borderline renal or cardiac function.
- ▶ **Bleeding problems.**

- ▶ A DERIVATIVE CARBENICILLIN INDANYL SODIUM GIVEN **ORALLY** FOR UTI AND OTHER LESS SERIOUS INFECTIONS.
- ▶ ACID STABLE ESTER OF CARBENICILLIN.

TICARCILLIN

- ▶ MORE POTENT AG. PSEUDOMONAS
- ▶ LESS ACTIVE THAN AMPICILLIN AGAINST ENTEROCOCCI.

UREIDOPENICILLIN

PIPERACILLIN

- ▶ 8 times more active than carbenicillin
- ▶ Good activity ag. Klebsiella
- ▶ Used mainly in immuno-compromised patients, having gram negative infections and in burns.
- ▶ Because of resistance problem antipseudomonal penicillin is combined with an aminoglycoside or fluoroquinolone.

MEZLOCILLIN

- ▶ INHIBITS KLEBSIELLA
- ▶ GIVEN PARENTERALLY FOR INFECTIONS CAUSED BY ENTERIC BACILLI.
- ▶ ACTIVITY SIMILAR TO TICARCILLIN AG. PSEUDOMONAS

BETA LACTAMASE INHIBITORS

- ▶ **BETA LACTAMASES** : Enzymes produced by gram positive and gram negative bacteria that inactivate beta lactam antibiotics by opening beta lactam ring .
- ▶ **BETA LACTAMASE INHIBITORS**
 - CLAVULANIC ACID
 - SULBACTAM
 - TAZOBACTAM

CLAVULANIC ACID

- ▶ FROM *streptomyces clavuligerus*
- ▶ Has beta lactam ring
- ▶ No antibacterial activity of its own
- ▶ Inhibits many beta lactamases
- ▶ Inhibition increases with time, initially reversible becomes covalent with time–Progressive inhibitor
- ▶ Irreversible binder
- ▶ Suicide inhibitor , gets inactivated after binding to the enzyme .
- ▶ Well absorbed by mouth, also given parenterally

- ▶ COMBINED WITH AMOXICILLIN AS AN ORAL PREP.
- ▶ WITH TICARCILLIN AS A PARENTERAL.
- ▶ AMOXICILLIN + CLAVULANATE EFFECTIVE FOR BETA LACTAMASE PRODUCING STRAINS OF STAPH (NOT MRSA) , H. INFLU, GONOCOCCI, E.COLI .

▶ **EFFECTIVE IN TREATMENT OF:**

- ▶ Skin & soft tissue infections
- ▶ Gynae infections
- ▶ Urinary & biliary infections
- ▶ Acute otitis media in children
- ▶ Sinusitis
- ▶ Bite wounds, cellulitis, diabetic foot infections.
- ▶ Addition of clavulanic acid to ticarcillin extends its spectrum such that it resembles imepenem to include aerobic gram negative bacilli, S. Aureus, bacteriodes .

- ▶ Dosage should be adjusted for patients with renal insufficiency.
- ▶ Combination is especially useful for mixed nosocomial infections, often used with aminoglycosides.
- ▶ Activity ag. *Pseudomonas* is not increased.
- ▶ Gut tolerance is poorer.
- ▶ Super-infections are more.
- ▶ Amoxicillin 250 + clavulanate 125 mg

SULBACTAM

- ▶ Semisynthetic Beta-lactamase inhibitor .
 - given orally/parenterally along with beta lactam antibiotic.
 - Combined with ampicillin.**
 - Dosage adjusted in patients with impaired renal fxn.
 - **Good activity ag. Gram positive cocci, including beta-lactamase producing strains of staph aureus, gram negative aerobes and anaerobes.**
 - Used effectively for mixed intra-abdominal and pelvic infections.

TAZOBACTAM

- ▶ Beta lactamase inhibitor
- ▶ Has been combined with **Piperacillin** as a parenteral prep.
- ▶ 3 g Piperacillin, 375 mg Tazobactam every 4– 8 hourly.
- ▶ Equal to Ticarcillin plus clavulanate.

CARBAPENEMS

- ▶ BETA LACTAMS THAT CONTAIN A FUSED β -lactam ring and a 5-membered ring system that differs from pen. In being unsaturated and containing a carbon atom instead of sulphur atom.
- ▶ Have a broader spectrum of activity than do most other β -lactam antibiotics have.

CARBAPENEMS

- ▶ IMIPENEM
- ▶ MEROPENEM
- ▶ ERTAPENEM

IMIPENEM

- ▶ DERIVED FROM A COMPOUND PRODUCED BY *STREPTOMYCES CATTLEYA*
- ▶ BINDS TO PBP_s, DISRUPTS BACTERIAL CELL WALL SYNTHESIS.
- ▶ VERY RESISTANT TO HYDROLYSIS BY MOST BETA LACTAMASES.

P/K

- ▶ NOT ABSORBED ORALLY
- ▶ IS RAPIDLY HYDROLYSED BY A DEHYDROPEPTIDASE FOUND IN THE BRUSH BORDER OF PROXIMAL RENAL TUBULES.
- ▶ GIVEN WITH AN INHIBITOR OF DEHYDROPEPTIDASE, CILASTATIN . A PREPARATION WITH EQUAL AMOUNTS OF BOTH.
- ▶ BOTH HAVE A HALF LIFE OF ONE HOUR.
- ▶ DOSE – 0.5 g i.v. 6 hourly.
- ▶ DOSAGE SHOULD BE MODIFIED FOR PATIENTS WITH RENAL INSUFFICIENCY.

ANTIMICROBIAL SPECTRUM

- ▶ IMIPENEM / CILASTATIN AND MEROPENEM ARE THE BROADEST SPECTRUM BETA LACTAM ANTIBIOTICS.
- ▶ PLAYS A ROLE IN EMPIRICAL THERAPY BECAUSE IT IS ACTIVE AGAINST PENICILLINASE PRODUCING GRAM- POSITIVE AND GRAM NEGATIVE ORGANISMS, ANAEROBES, AND *P. AERUGINOSA*.
- ▶ *STREPTOCOCCI* (INCL. PENICILLIN RESISTANT *S.PNEUMONIAE*), *ENTEROCOCCI*, *STAPH*, *LISTERIA*, *SOME STRAINS OF MRSA*, *ACINETOBACTER*, *B. FRAGILIS*.

ADVERSE EFFECTS

- ▶ NAUSEA & VOMITING
- ▶ SEIZURES , WHEN HIGH DOSES GIVEN IN PATIENTS WITH CNS LESIONS AND THOSE WITH RENAL INSUFFICIENCY.
- ▶ ALLERGIC TO PEN. MAY SHOW HYPERSENSITIVITY.
- ▶ LESSER EOSINOPHILIA AND NEUTROPENIA

THERAPEUTIC USES

- ▶ **IMIPENEM / CILASTATIN FOR**
- ▶ UTI , LOWER RESPIRATORY TRACT INFECTIONS, INTRAABDOMINAL AND GYNAECOLOGICAL INFECTIONS.
- ▶ SKIN AND SOFT TISSUE , BONE AND JOINT INFECTIONS .
- ▶ DRUG COMBINATION **ESP. USEFUL FOR** INFECTIONS CAUSED BY CEPHALOSPORIN-RESISTANT NOSOCOMIAL BACT, SUCH AS CITROBACTER AND ENTEROBACTER
- ▶ FOR EMPIRICAL TREATMENT OF SERIOUS INF. IN HOSPITALISED PT .
- ▶ **SHOULD NOT DE USED ALONE – RESISTANCE RISK**

Imipenem



Figure 31.14
Antimicrobial spectrum of *imipenem*.

MEROPENEM

- ▶ DOES NOT REQUIRE CO-ADMINISTRATION WITH CILASTATIN, NOT SENSITIVE TO RENAL DIPEPTIDASE.
- ▶ LESS LIKELY TO CAUSE SEIZURES.
- ▶ ACTIVITY AG. P. AERUGINOSA.
- ▶ LESS ACTIVITY AG GRAM + VE COCCI.
- ▶ THERAPEUTICALLY EQ.TO IMIPENEM

MONOBACTAMS

AZTREONAM

- ▶ MONOCYCLIC BETA LACTAM COMP.
- ▶ BETA LACTAM RING IS NOT FUSED TO ANOTHER RING .
- ▶ ISOLATED FROM *CHROMOBACTERIUM VIOLACEUM*
- ▶ INTERACTS WITH PBP_s OF SUSCEPTIBLE BACT, INDUCES THE FORMATION OF LONG FILAMENTOUS BACT. STRUCTURES.

ANTIBACT.ACTIVITY

- ▶ DIFFERS FROM BETA LACTAM, RESEMBLES AMINOGLYCOSIDES
- ▶ GRAM +VE AND ANAEROBES ARE RESISTANT .
- ▶ EXCELLENT ACT. AG. –
ENTEROBACTERIACEAE , PSEUDOMONAS,
H.INFLU (At very low conc.) , GONOCOCCI .
- ▶ RES.TO ACTION OF MANY BETA LACTAMASES.

P/K

- ▶ ADM. I/M OR I/V
- ▶ ELIMINATION HALF LIFE 1.7 HOURS
- ▶ CAN ACCUMULATE IN PTs. WITH RENAL FAILURE.
- ▶ USUAL DOSE FOR SERIOUS INFECTIONS – 2 g 6–8 HOURLY, BUT DECREASED IN RENAL DS PTs.

S/Es

- ▶ WELL TOLERATED
- ▶ LOW IMMUNOGENIC POT.
- ▶ MAIN ADVANTAGE – PATIENTS WHO ARE ALLERGIC TO PENICILLINS OR CEPHALOSPORINS DO NOT REACT TO AZTREONAM.
- ▶ QUITE USEFUL FOR TREATING GRAM NEGATIVE INFECTIONS, THAT COULD BE TREATED WITH ABOVE DRUGS, BUT H/O ALLERGY WAS THERE.

CEPHALOSPORINS

- ▶ Produced semisynthetically by chemical attachment of side chains to 7-amincephalosporanic acid.

Same mode of action , same resistance mech. But tend to be more resistant than penicillins to certain beta -lactamases .

ANTIBACTERIAL SPECTRUM

- ▶ CLASSIFIED AS FIRST, SECOND, THIRD OR FOURTH GENERATION BASED ON :
 - BACTERIAL SUSCEPTIBILITY PATTERNS
 - RESISTANCE TO BETA -LACTAMASES
- ▶ NOT EFFECTIVE AGAINST –
- ▶ *MRSA , L. MONOCYTOGENES , C. DIFFICLE , ENTEROCOCCI*

C/F

FIRST GENERATION

- ▶ PARENTERAL –
- ▶ CEPHALOTHIN
- ▶ CEFAZOLIN
- ▶ ORAL –
- ▶ CEPHALEXIN
- ▶ CEPHRADINE
- ▶ CEFADROXIL

SECOND GENERATION

- ▶ PARENTERAL
- ▶ CEFUROXIME
- ▶ CEFOXITIN

- ▶ ORAL
- ▶ CEFACLOR
- ▶ CEFUROXIME AXETIL

THIRD GENERATION

- ▶ PARENTERAL

- ▶ CEFOTAXIME

CEFTIZOXIME

- ▶ CEFTRIAZONE

CEFTAZIDIME

- ▶ CEFOPERAZONE

- ▶ ORAL

- ▶ CEFIXIME

CEFPODOXIME

- ▶ CEFDINIR

CEFTIBUTEN

FOURTH GENERATION

- ▶ PARENTERAL
- ▶ CEFEPIME
- ▶ CEFPIROME

Table 7–2. Clinical uses of cephalosporins.

Cephalosporins	Infections
First generation: cefazolin, cephalexin	Gram-positive cocci (not MRSA), <i>Escherichia coli</i> , <i>Klebsiella pneumoniae</i> , and some <i>Proteus</i> species
Second generation: cefotetan, cefaclor	Gram-negative bacilli including <i>Bacteroides fragilis</i> (cefotetan); <i>Hemophilus influenzae</i> and <i>Moraxella catarrhalis</i> (cefaclor)
Third generation	Many gram-positive and gram-negative cocci and gram-negative bacilli including β -lactamase-forming strains; individual drugs have activity against specific organisms including <i>Pseudomonas</i> (ceftazidime), anaerobes (ceftizoxime), and gonococci (ceftriaxone, cefixime)
Fourth generation	Cefipime combines the gram-positive activity of the first-generation drugs with the gram-negative activity of the third-generation drugs

B. Clinical Uses

1. Clinical uses of cephalosporins vary depending on the generation of the drug.
2. Table 7–2 lists the clinical uses of cephalosporins.

FIRST GENERATION

CEPHALOTHIN

- ▶ ACTIVE AGAINST MOST Penicillin G SENSITIVE ORG. i.e.
- ▶ Streptococci (pyogenes & viridans), staphylococcus (including those producing penicillinase), not MRSA
- ▶ Gonococci, meningococci, C.diphtheriae Clostridia, actinomyces
- ▶ Main indication – penicillinase producing staph
- ▶ i.v. 1 –2 g 6 hrly (i/m Painful)

CEFAZOLIN

- ▶ MORE ACTIVE AG. KLEBSIELLA & E.COLI
- ▶ SUSCEPTIBLE TO STAPH BETA-LACTAMASE
- ▶ PREFERRED PARENTERAL FIRST GEN
SPECIALLY FOR SURGICAL PROPHYLAXIS
- ▶ Can be given i.m. also, less painful
- ▶ 0.25 g 8 hourly, 1 g 6 hrly i.m , i.v.

CEPHALEXIN

- ▶ Orally effective
- ▶ Similar to cephalothin in spectrum , but less active ag. Penicillinase producing staph and ag. H .influenzae.
- ▶ Little bound to plasma proteins, attains high conc. In bile.
- ▶ Excreted unchanged in urine
- ▶ 0.25 - 1 g 6-8 hrly

CEPHRADINE

- ▶ ORALLY ACTIVE , SIMILAR TO CEPHALEXIN
- ▶ DIARRHOEA
- ▶ PARENTERAL ALSO

▶ **CEFADROXIL**

- ▶ A CLOSE CONGENER OF CEPHALEXIN
- ▶ GOOD TS. PENETRATION
- ▶ MORE SUSTAINED ACTION AT THE SITE OF INFECTION
- ▶ CAN BE GIVEN 12 HRLY, EXCRETED UNCHANGED IN URINE

SECOND GENERATION CEPHALOSPORINS

CEFOXITIN

- ▶ MORE ACTIVE AGAINST SERRATIA, INDOLE POSITIVE PROTEUS, B.FRAGILIS
- ▶ HIGHLY RESISTANT TO B-LACTAMASES PRODUCED BY GRAM -VE BACT.
- ▶ ANEROBIC & MIXED OBS/ SURGICAL INF.
- ▶ LUNG ABSCESS
- ▶ DOSE - 1-2 g I.M / I.V EVERY 6-8 HRS

CEFUROXIME

- ▶ RESISTANT TO BETA-LACTAMASES PRODUCED BY GRAM -VE BACTERIA .
- ▶ HIGH ACTIVITY AG. ORG. PRODUCING THESE ENZYMES INCL. PPNG AND AMPICILLIN RESISTANT H.INFLUENZAE .
- ▶ HAVE SIGNIFICANT ACTIVITY ON GRAM POSITIVE COCCI.
- ▶ ATTAINS HIGH CSF LEVELS
- ▶ MOST IMP. USE IS MENINGITIS CAUSED BY H.INFLUENZAE , MENINGOCOCCI , PNEUMOCOCCI

CEFACLOR

- ▶ HIGHLY SIGNIFICANT ACTIVITY BY ORAL ROUTE
- ▶ MORE ACTIVE THAN FIRST GEN. COMP. AGAINST *H.INFLUENZAE* , *E.COLI* , *P.MIRABILIS*

THIRD GENERATION CEPHALOSPORINS

- ▶ HIGH ACTIVITY AGAINST GRAM NEGATIVE ENTEROBACTERIACEAE
- ▶ PSEUDOMONAS
- ▶ RESISTANT TO BETA-LACTAMASES FROM GRAM NEGATIVE BACT.
- ▶ LESS ACTIVE ON GRAM POSITIVE COCCI

CEFOTAXIME

- ▶ PROTOTYPE
- ▶ AEROBIC GRAM NEGATIVE & GRAM POSITIVE BACT.
- ▶ NOT VERY ACTIVE ON ANEROBES , STAPH , Ps. AERUGINOSA
- ▶ **INDICATIONS** – MENINGITIS BY GRAM –VE
- ▶ LIFE THREATENING HOSPITAL ACQUIRED INFECTION, SEPTICEMIAS
- ▶ INFECTION IN IMMUNOCOMPROMISED PATIENTS

- ▶ 1–2 g i.m. or i.v. 6–12 hrly
- ▶ Single dose therapy (1 g i.m. and 1 g probenecid) for PPNG urethritis.
- ▶ De-acetylated in the body
- ▶ Metabolite exerts weaker but synergistic action with the parent drug .

CEFTRIAXONE

- ▶ Longer duration of action (half life 8 hrs)
- ▶ Once or twice daily dosing
- ▶ Good CSF penetration
- ▶ High efficacy in bacterial meningitis
- ▶ Multi- resistant typhoid fever
- ▶ Complicated UTI
- ▶ Abdominal sepsis ,Septicemias
- ▶ A single dose of 250 mg. i.m. – curative in gonorrhoea including PPNG and chancroid .

CEFTAZIDIME

- ▶ High activity ag. Pseudomonas
- ▶ Sp. useful in febrile neutropenic pts. with hematological malignancy, burn.
- ▶ Enterobacteriaceae
- ▶ Less active on staph. aureus and gram positive cocci.
- ▶ Half life 1.5–1.8 hr.
- ▶ Neutropenia, thrombocytopenia , rise in plasma trans-aminases and blood urea has been reported.

CEFOPERAZONE

- ▶ STRONGER ACTIVITY ON PSEUDOMONAS
- ▶ GOOD FOR S.TYPHI & B. FRAGILIS
- ▶ MORE SUSCEPTIBLE TO β -LACTAMASES
- ▶ INDICATIONS --
- ▶ SEVERE URINARY, BILIARY, RESPIRATORY, SKIN-SOFT TS. INFECTIONS, MENINGITIS, SEPTICAEMIAS
- ▶ .
- ▶ EXCRETED MAINLY IN BILE
- ▶ DISULFIRAM LIKE REACTION WITH ALCOHOL.

CEFIXIME

- ▶ ORALLY ACTIVE WITH HIGH ACTIVITY ag. Entero-bacteriaceae, H.Influenzae, strep. Pyogenes , strep. Pneumoniae
- ▶ Resistant to many beta lactamases.
- ▶ Longer acting .
- ▶ 200–400 mg b.d. For respiratory, urinary & biliary infections .
- ▶ Diarrhea common side effect.

CEFPODOXIME

- ▶ ORALLY ACTIVE , PRODRUG
- ▶ ENTEROBACT, STREP, STAPH
- ▶ RESPIRATORY , URINARY , BILIARY INF.

CEFDINIR

- ▶ GOOD ACTIVITY Ag. BETA LACTAMASE PRODUCING ORG.
- ▶ PNEUMONIA , ACUTE EXACERBATIONS OF CHRONIC BRONCHITIS , ENT, SKIN INFECTIONS .

CEFTIBUTEN

- ▶ ACTIVE AG. BOTH GRAM POSITIVE AND NEGATIVE
- ▶ STABLE TO BETA LACTAMASES
- ▶ INDICATED IN RESPIRATORY, URINARY , GI INFECTIONS

FOURTH GENERATION CEPH.

CEFEPIME

- ▶ HIGHLY RESISTANT TO BETA- LACTAMASES
- ▶ SPECTRUM SIMILAR TO THIRD GEN
- ▶ ADDITIONAL ACTIVITY AG. BACTERIA RESISTANT TO OTHER DRUGS .
- ▶ P. AERUGINOSA, STAPH ALSO INHIBITED
- ▶ EFFECTIVE IN MANY SERIOUS INFECTIONS LIKE NOSOCOMIAL , FEBRILE NEUTROPENIA , BACTEREMIA, SEPTICAEMIA
- ▶ 1-2 g i.v. 8-12 hrly

CEFPIROME

- ▶ SERIOUS AND RESISTANT HOSPITAL ACQUIRED INFECTIONS
- ▶ SEPTICEMIAS
- ▶ LOWER RESP. TRACT INFECTIONS
- ▶ BETTER PENETRATION THROUGH PORIN CHANNELS OF GRAM NEGATIVE BACTERIA
- ▶ RESISTANT TO MANY BETA-LACTAMASES

S/Es of Cephalosporins

- ▶ Local irritation can produce severe pain after i.M. Injection, thrombophlebitis after i.v.
- ▶ Diarrhoea due to disturbed gut ecology
- ▶ Hypersensitivity reactions similar to Penicillins including anaphylaxis, fever, skin rashes, nephritis, granulocytopenia and hemolytic anemia. Cross allergenicity around 5–10 % .
- ▶ Nephrotoxicity including interstitial nephritis and even tubular necrosis, highest with cephaloridine (withdrawn) cephalothin also causes.

S/Es

- ▶ Hypoprothrombinemia and bleeding disorders by cefamandole , cefmetazole, cefotetan , cefoperazone
vit. K 10 mg twice weekly can prevent it.
- ▶ A disulfiram like interaction with alcohol with cefoperazone .
- ▶ Neutropenia and thrombocytopenia rarely, with ceftazidime.




Figure 49.3 Schematic diagram of the biosynthesis of peptidoglycan in a bacterial cell (e.g. *Staphylococcus aureus*), with the sites of action of various antibiotics. The hydrophilic disaccharide-pentapeptide is transferred across the lipid cell membrane attached to a large lipid (C₅₅ lipid) by a pyrophosphate bridge (-P-P-). On the outside, it is enzymically attached to the 'acceptor' (the growing peptidoglycan layer). The final reaction is a transpeptidation, in which the loose end of the (Gly)₅ chain is attached to a peptide side-chain of an M in the acceptor and during which the terminal amino acid (alanine) is lost. The lipid is regenerated by loss of a phosphate group (Pi) before functioning again as a carrier. G, N-acetylglucosamine; M, N-acetylmuramic acid; UDP, uridine diphosphate; UMP, uridine monophosphate.